GO:0070104 negative regulation of interleukin-6-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070104 describes any process that decreases the rate, frequency or extent of interleukin-6 (IL-6)-mediated signaling.
• Negative regulation of IL-6 signaling is critical for limiting inflammation, controlling STAT3 activation, and preventing tumor progression.
• Key negative regulators include protein tyrosine phosphatases such as TC-PTP, which dephosphorylates STAT3, and PTEN, which suppresses the PI3K/Akt arm of IL-6 signaling.
• Dysregulation of this process contributes to cancers (breast, prostate, myeloma, basal cell carcinoma), sepsis, and smoke-related diseases.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators in IL-6 signaling.
• Studying GO:0070104 requires integrated approaches: phospho-proteomics, reporter assays, and functional genomics.
Description
Interleukin-6 (IL-6) is a pleiotropic cytokine that activates the JAK/STAT3, PI3K/Akt, and MAPK pathways, driving inflammation, cell survival, and proliferation. The Gene Ontology term GO:0070104, negative regulation of interleukin-6-mediated signaling pathway, encompasses any process that decreases the rate, frequency or extent of IL-6 signaling. This regulatory process is essential for resolving inflammation and preventing pathological hyperactivation of IL-6 responses. Researchers study GO:0070104 to understand how cells terminate IL-6 signals, how this fails in disease, and how to therapeutically target negative regulators. The term is particularly relevant in cancer biology, where constitutive STAT3 activation and PI3K/Akt signaling promote tumor growth and survival. In sepsis, myocardial depression caused by IL-6 is modulated by p38 MAPK, highlighting the importance of negative regulatory mechanisms. Environmental factors such as smoke exposure can alter DNA methylation and gene expression, potentially impacting IL-6 signaling regulation. Thus, GO:0070104 represents a convergence point for cytokine signaling, phosphatase activity, and disease pathogenesis.
negative regulation of interleukin-6-mediated signaling pathway At A Glance
| GO ID | GO:0070104 |
|---|---|
| GO term | negative regulation of interleukin-6-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of IL-6-mediated signaling pathway; negative regulation of interleukin-6-mediated signalling pathway |
| Major function | Attenuation of IL-6-induced JAK/STAT3, PI3K/Akt, and MAPK signaling |
| Key negative regulators | TC-PTP (PTPN2), PTEN, SOCS proteins, p38 MAPK (context-dependent) |
| Associated diseases | Breast cancer, prostate cancer, multiple myeloma, basal cell carcinoma, meningococcal sepsis |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, phospho-STAT3 immunoblotting, luciferase reporter assays, Ribo-seq, proteomics |
What Is GO:0070104?
GO:0070104 is defined as any biological process that decreases the rate, frequency or extent of an interleukin-6-mediated signaling pathway. In practice, this includes the action of phosphatases that dephosphorylate JAK or STAT3, suppressors of cytokine signaling (SOCS) proteins, and lipid phosphatases like PTEN that antagonize the PI3K/Akt branch of IL-6 signaling. Negative regulation can occur at multiple levels: receptor internalization, kinase inactivation, or transcriptional feedback. The term is a child of negative regulation of cytokine-mediated signaling pathway and is specific to IL-6.
Why Is negative regulation of interleukin-6-mediated signaling pathway Important in Cell Biology?
Negative regulation of IL-6-mediated signaling is essential for maintaining immune homeostasis and preventing chronic inflammation and cancer. IL-6 is a major driver of STAT3 activation, which promotes survival and proliferation in many malignancies. Without negative regulation, constitutive IL-6 signaling leads to uncontrolled cell growth, angiogenesis, and metastasis. In sepsis, excessive IL-6 contributes to myocardial depression, and p38 MAPK acts as a negative regulator of this effect. Environmental exposures like smoking can alter DNA methylation, potentially disrupting negative feedback loops and contributing to disease. Therefore, understanding GO:0070104 provides insights into disease mechanisms and identifies therapeutic targets.
• Prevents chronic inflammation by terminating IL-6 signals.
• Suppresses tumor growth by inhibiting STAT3 and PI3K/Akt pathways.
• Modulates angiogenesis in breast tumors via VEGFR2 epigenetic control.
• Regulates apoptosis in basal cell carcinoma through Mcl-1 downregulation.
• Protects against sepsis-induced myocardial depression.
• Influences smoke-related disease etiology via DNA methylation changes.
• Provides targets for cancer therapy, e.g., PTEN restoration in myeloma.
• Key for understanding cytokine signaling feedback and cross-talk.
• Enables development of CRISPR models to dissect gene function.
• Guides biomarker discovery in inflammatory and malignant diseases.
What Happens During negative regulation of interleukin-6-mediated signaling pathway?
Receptor-level attenuation
In simple terms: Cells reduce the number of IL-6 receptors or block their activation to stop the signal early.
Negative regulation can occur by internalization or degradation of the IL-6 receptor complex, or by inhibition of JAK kinases. While specific mechanisms are not detailed in the provided citations, the general principle is that reducing receptor availability limits downstream signaling.
STAT3 dephosphorylation by phosphatases
In simple terms: Enzymes called phosphatases remove phosphate groups from STAT3, turning off the signal.
The nuclear isoform of protein-tyrosine phosphatase TC-PTP (PTPN2) dephosphorylates STAT3, thereby negatively regulating IL-6-mediated signaling. This represents a direct enzymatic mechanism to terminate STAT3 activation.
PI3K/Akt pathway suppression by PTEN
In simple terms: PTEN acts as a brake on the PI3K/Akt survival pathway that IL-6 can activate.
PTEN, but not SHIP or SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis in myeloma cells. Since IL-6 can activate PI3K/Akt, PTEN acts as a negative regulator of this branch of IL-6 signaling.
Modulation by p38 MAPK in sepsis
In simple terms: In severe infections, p38 MAPK can dampen the harmful effects of IL-6 on the heart.
Myocardial depressant effects of IL-6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase. This indicates that p38 MAPK can act as a negative regulator of IL-6 effects in a context-dependent manner.
Epigenetic control of downstream targets
In simple terms: IL-6 signaling can be influenced by epigenetic changes that alter gene expression.
IL-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors. Negative regulation may involve reversing such epigenetic modifications, though specific mechanisms require further study.
Key Genes Involved in GO:0070104 negative regulation of interleukin-6-mediated signaling pathway
The following genes and proteins are central to the negative regulation of IL-6-mediated signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN2 (TC-PTP) | Dephosphorylates STAT3 to terminate IL-6 signaling | Key negative regulator; target for enhancing IL-6 signaling in autoimmunity |
| PTEN | Suppresses PI3K/Akt pathway, antagonizes IL-6 survival signals | Tumor suppressor; frequently lost in cancers |
| STAT3 | Transcription factor activated by IL-6; target of negative regulation | Central node; constitutive activation in many cancers |
| JAK1/2 | Kinases that phosphorylate STAT3 upon IL-6 stimulation | Upstream activators; negative regulation can occur via phosphatases |
| SOCS1/3 | Feedback inhibitors of JAK/STAT signaling | Classic negative regulators; not directly cited but implied by pathway |
| PIK3CA | Catalytic subunit of PI3K; activated by IL-6 | Oncogene; PTEN opposes its activity |
| AKT1 | Survival kinase downstream of PI3K | Promotes anti-apoptosis; inhibited by PTEN |
| MCL1 | Anti-apoptotic protein upregulated by IL-6 via PI3K/Akt | Target of negative regulation; high in basal cell carcinoma |
| VEGFR2 | Angiogenesis receptor epigenetically controlled by IL-6 | Implicated in breast tumor angiogenesis |
| MAPK14 (p38α) | Stress kinase that can negatively regulate IL-6 effects | Context-dependent regulator in sepsis |
| IL6R | IL-6 receptor; initiates signaling | Target for blockade; negative regulation at receptor level |
| IL6ST (gp130) | Signal-transducing subunit | Common to IL-6 family cytokines; negative regulation affects downstream |
| PTPN11 (SHP2) | Phosphatase that can modulate JAK/STAT | Potential negative regulator; not directly cited |
| CISH | Cytokine-inducible SH2-containing protein | Feedback inhibitor of STAT5; may cross-regulate |
| PIAS3 | Protein inhibitor of activated STAT3 | Negative regulator of STAT3 DNA binding |
| NR0B2 (SHP) | Small heterodimer partner; can inhibit STAT3 | Potential negative regulator; not directly cited |
| SOCS3 | Potent inhibitor of gp130 signaling | Key feedback inhibitor; implied by pathway |
| PTPRC (CD45) | Phosphatase that can dephosphorylate JAK | Broad negative regulator; not directly cited |
How Is negative regulation of interleukin-6-mediated signaling pathway Regulated?
The negative regulation of IL-6-mediated signaling is itself tightly controlled. TC-PTP (PTPN2) is a nuclear phosphatase that dephosphorylates STAT3, and its activity can be regulated by cellular localization and expression levels. PTEN lipid phosphatase activity is controlled by phosphorylation, ubiquitination, and subcellular localization, and its loss leads to enhanced PI3K/Akt signaling downstream of IL-6. In sepsis, p38 MAPK activity modulates the myocardial depressant effects of IL-6, suggesting that p38 activation can negatively regulate IL-6 responses in the heart. Additionally, epigenetic changes such as DNA methylation, which can be altered by smoke exposure, may influence the expression of negative regulators. These layers of regulation ensure that IL-6 signaling is transient and appropriate to the context.
negative regulation of interleukin-6-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTPN2 | Autoimmunity, cancer | Knockout in Jurkat or HeLa cells; phospho-STAT3 readout |
| PTEN | Multiple myeloma, prostate cancer | Knockout in myeloma cell lines; PI3K/Akt and apoptosis assays |
| STAT3 | Prostate cancer, breast cancer | Point mutation (constitutive activation) in cancer cell lines |
| MCL1 | Basal cell carcinoma | Overexpression in basal cell carcinoma cells; apoptosis assays |
| VEGFR2 | Breast tumor angiogenesis | Knock-in of methylation-sensitive promoter; angiogenesis assays |
Cancer
Dysregulation of negative regulation of IL-6 signaling is implicated in multiple cancers. In breast tumors, IL-6-mediated epigenetic control of VEGFR2 induces disorganized angiogenesis. In prostate cancer, inhibition of constitutively activated STAT3 suppresses growth, indicating that loss of negative regulation contributes to tumor progression. In multiple myeloma, PTEN suppresses PI3K/Akt and induces apoptosis, but its loss leads to enhanced IL-6 survival signaling. In basal cell carcinoma, IL-6 upregulates Mcl-1 via PI3K/Akt to promote anti-apoptosis.
Sepsis and inflammation
In meningococcal sepsis, IL-6 contributes to myocardial depression, which is regulated by p38 MAPK. This suggests that p38 MAPK acts as a negative regulator of IL-6 effects in the heart, and its dysregulation may worsen cardiac dysfunction.
Environmental and epigenetic diseases
Smoke-related DNA methylation changes can alter the expression of genes involved in IL-6 signaling, potentially disrupting negative feedback and contributing to disease etiology.
From negative regulation of interleukin-6-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTPN2 enhance IL-6/STAT3 signaling? | CRISPR knockout of PTPN2 in HeLa or HepG2 cells |
| Does PTEN suppression of PI3K/Akt require its lipid phosphatase activity? | Point mutation (C124S) knock-in in PTEN-null cells |
| Can constitutive STAT3 activation drive prostate cancer growth? | Knock-in of STAT3-C (A661C/N663C) in prostate cancer cells |
| Does IL-6-induced VEGFR2 expression depend on promoter methylation? | Knock-in of methylated VEGFR2 promoter reporter |
| Does p38 MAPK inhibition alter IL-6 myocardial depression? | Knockout of MAPK14 in cardiomyocytes |
| Does overexpression of SOCS3 block IL-6 signaling? | Overexpression of SOCS3 in IL-6-responsive cells |
How to Study the negative regulation of interleukin-6-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunoblotting | Phospho-STAT3, phospho-Akt levels | Assess negative regulation after IL-6 stimulation |
| Luciferase reporter | STAT3 transcriptional activity | Screen for regulators of IL-6 signaling |
| CRISPR knockout screen | Gene essentiality for negative regulation | Identify novel negative regulators |
| Phospho-proteomics | Global phosphorylation changes | Map signaling networks downstream of IL-6 |
| Bisulfite sequencing | DNA methylation status | Link epigenetic changes to IL-6 signaling |
| qRT-PCR | mRNA levels of target genes (e.g., MCL1, VEGFR2) | Measure downstream effects of negative regulation |
| Apoptosis assay | Cell survival/apoptosis | Evaluate PTEN-mediated suppression of PI3K/Akt |
| Angiogenesis assay | Tube formation | Study IL-6-mediated angiogenesis in breast tumors |
Phospho-proteomics and immunoblotting
To study negative regulation of IL-6 signaling, researchers measure phosphorylation of STAT3, JAK, and Akt using immunoblotting or phospho-proteomics. TC-PTP dephosphorylates STAT3, which can be detected by reduced phospho-STAT3 levels. PTEN activity can be assessed by phospho-Akt levels.
Reporter assays
STAT3-responsive luciferase reporters are used to quantify IL-6-induced transcriptional activity and its suppression by negative regulators. This method is sensitive and scalable for high-throughput screening.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of IL-6 signaling. Cells are stimulated with IL-6, and reporters or phospho-STAT3 readouts are used to sort regulators.
Epigenetic analysis
DNA methylation of genes such as VEGFR2 can be assessed by bisulfite sequencing or methylation-specific PCR, linking epigenetic changes to IL-6 signaling regulation.
How CRISPR Can Be Used to Study GO:0070104 negative regulation of interleukin-6-mediated signaling pathway
Knockout
CRISPR knockout of negative regulators such as PTPN2 or PTEN can be used to assess their role in IL-6 signaling. For example, PTPN2 knockout in HeLa cells leads to increased STAT3 phosphorylation upon IL-6 stimulation. PTEN knockout in myeloma cells enhances PI3K/Akt signaling and resistance to apoptosis.
Point Mutation
Point mutations can be introduced to study specific residues critical for negative regulator function. For instance, a catalytically dead PTEN (C124S) can be knocked in to determine if its lipid phosphatase activity is required for suppressing PI3K/Akt. Similarly, STAT3 point mutations (e.g., A661C/N663C) can create constitutively active forms to model loss of negative regulation.
Knock-in
Knock-in of reporter genes or tagged versions of negative regulators allows real-time monitoring of their expression and localization. For example, a luciferase reporter knocked into the VEGFR2 locus can be used to study IL-6-mediated epigenetic control. Tagged TC-PTP knock-in enables tracking of its nuclear translocation.
Overexpression
Overexpression of negative regulators such as PTEN or SOCS3 can suppress IL-6 signaling and its downstream effects. PTEN overexpression in myeloma cells inhibits PI3K/Akt and induces apoptosis. Overexpression of TC-PTP reduces STAT3 phosphorylation and IL-6-mediated gene expression.
How EDITGENE Supports negative regulation of interleukin-6-mediated signaling pathway Research
Researchers studying negative regulation of interleukin-6-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in attenuating IL-6 signals or is merely a bystander. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-6-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of interleukin-6-mediated signaling pathway
What is GO:0070104?
GO:0070104 is the Gene Ontology term for negative regulation of interleukin-6-mediated signaling pathway, describing any process that decreases the rate, frequency or extent of IL-6 signaling.
What genes are involved in negative regulation of IL-6 signaling?
Key genes include PTPN2 (TC-PTP), PTEN, SOCS1/3, and PIAS3, which dephosphorylate STAT3, suppress PI3K/Akt, or inhibit STAT3 DNA binding.
How does TC-PTP negatively regulate IL-6 signaling?
TC-PTP dephosphorylates STAT3, thereby terminating IL-6-induced STAT3 activation.
What is the role of PTEN in IL-6 signaling?
PTEN suppresses the PI3K/Akt pathway, which is activated by IL-6, thereby inhibiting survival and promoting apoptosis.
Which diseases are linked to defective negative regulation of IL-6 signaling?
Cancers such as breast, prostate, and multiple myeloma, as well as sepsis and smoke-related diseases, are associated with dysregulated negative regulation.
How can CRISPR be used to study negative regulation of IL-6 signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of negative regulators in cell lines.
What methods measure negative regulation of IL-6 signaling?
Immunoblotting for phospho-STAT3, luciferase reporter assays, phospho-proteomics, and apoptosis assays are commonly used.
Is p38 MAPK a negative regulator of IL-6 signaling?
In meningococcal sepsis, p38 MAPK regulates the myocardial depressant effects of IL-6, acting as a context-dependent negative regulator.
What is the connection between IL-6 and VEGFR2 in breast cancer?
IL-6 mediates epigenetic control of the VEGFR2 gene, inducing disorganized angiogenesis in breast tumors.
How does smoke exposure affect IL-6 signaling regulation?
Smoke-related DNA methylation changes can alter gene expression, potentially impacting negative feedback loops in IL-6 signaling.
Conclusion
GO:0070104, negative regulation of interleukin-6-mediated signaling pathway, is a critical process for controlling inflammation and preventing cancer. Key negative regulators such as TC-PTP and PTEN terminate IL-6 signals through STAT3 dephosphorylation and PI3K/Akt suppression. Dysregulation of this process contributes to breast, prostate, and hematological cancers, as well as sepsis and environmental diseases. CRISPR-based models are indispensable for dissecting these mechanisms and identifying therapeutic targets. EDITGENE provides comprehensive services to accelerate research in this field.
References
- 1. Hegde M et al.. 2020. Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors.. J Biol Chem 295(34):12086-12098 PMID: 32636303
- 2. Yamamoto T et al.. 2002. The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation.. Biochem Biophys Res Commun 297(4):811-7 PMID: 12359225
- 3. Jee SH et al.. 2002. The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells.. J Invest Dermatol 119(5):1121-7 PMID: 12445202
- 4. Ni Z et al.. 2000. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.. Cancer Res 60(5):1225-8 PMID: 10728680
- 5. Pathan N et al.. 2011. Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase.. Crit Care Med 39(7):1692-711 PMID: 21494108
- 6. Besingi W et al.. 2014. Smoke-related DNA methylation changes in the etiology of human disease.. Hum Mol Genet 23(9):2290-7 PMID: 24334605
- 7. Choi Y et al.. 2002. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.. Oncogene 21(34):5289-300 PMID: 12149650
